| Literature DB >> 35741690 |
Barbara Mavroidi1, Archontia Kaminari1, Dimitris Matiadis1, Dimitra Hadjipavlou-Litina2, Maria Pelecanou1, Athina Tzinia1, Marina Sagnou1.
Abstract
Alzheimer's disease (AD) is a multifactorial disorder strongly involving the formation of amyloid-β (Aβ) oligomers, which subsequently aggregate into the disease characteristic insoluble amyloid plaques, in addition to oxidative stress, inflammation and increased acetylcholinesterase activity. Moreover, Aβ oligomers interfere with the expression and activity of Glycogen synthase kinase-3 (GSK3) and Protein kinase B (PKB), also known as AKT. In the present study, the potential multimodal effect of two synthetic isatin thiosemicarbazones (ITSCs), which have been previously shown to prevent Aβ aggregation was evaluated. Both compounds resulted in fully reversing the Aβ-mediated toxicity in SK-NS-H cells treated with exogenous Aβ peptides at various pre-incubation time points and at 1 μM. Cell survival was not recovered when compounds were applied after Aβ cell treatment. The ITSCs were non-toxic against wild type and 5xFAD primary hippocampal cells. They reversed the inhibition of Akt and GSK-3β phosphorylation in 5xFAD cells. Finally, they exhibited good antioxidant potential and moderate lipoxygenase and acetylcholinesterase inhibition activity. Overall, these results suggest that isatin thiosemicarbazone is a suitable scaffold for the development of multimodal anti-AD agents.Entities:
Keywords: Akt; Aβ cytotoxicity; GSK-3β; acetylcholinesterase inhibitors; isatin thiosemicarbazones
Year: 2022 PMID: 35741690 PMCID: PMC9221192 DOI: 10.3390/brainsci12060806
Source DB: PubMed Journal: Brain Sci ISSN: 2076-3425
Figure 1Chemical structure of the tested isatin thiosemicarbazones.
Figure 2ITSC derivatives effectively protect against neurotoxicity caused by Aβ42 in SK-N-SH cells: (a) Mixtures of either M or FMp (1 and 2 μΜ) with Aβ42 (1 μΜ) were incubated for 24 h at 37 °C and then added to cells for 24 h. Negative control cells were treated with ITSCs alone in the same conditions. (b) Cells were treated with either M or FMp (1 μM) for 1, 3, 5 and 24 h prior to the addition of Aβ42 (1 μΜ) for 24 h. (c) Cells were treated for 24 h with 1 μΜ of Aβ42 followed by a 24 h treatment with 1 μΜ of M or FMp. Significance relative to control (a) and to Aβ42 (b,c). Results were expressed as the mean ± s.d. for at least three independent experiments and analyzed using one-way ANOVA (**** p < 0.0001).
Figure 3Cell viability of primary hippocampal cells upon treatment with ITSCs. Cells isolated from wild type (WT) and 5xFAD mice were treated for 24 h with 10 μM of M (a) and FMp (b). Results were expressed as the mean ± s.d. for at least three independent experiments and analyzed using two-way ANOVA.
Figure 4ITSCs derivatives reverse the inhibition of Akt and GSK-3β phosphorylation in 5xFAD cells. Primary hippocampal cells isolated from wild type (WT) and 5xFAD mice were treated for 24 h with (1 μM) of M (a) and FMp (b). Equal amounts of total protein were analyzed on 10% SDS-PAGE gels and immunoblotted with primary antibodies against phosphorylated AKT and GSK-3β kinases. Graphs depict densitometric quantification of phosphorylated proteins normalized to their housekeeping gene β-Tubulin or β-Actin. Results are expressed as the mean ± s.d. for at least three independent experiments and analyzed using a student t test (* p < 0.05, ** p < 0.01).
In vitro inhibition of soybean lipoxygenase (IC50 μΜ), in vitro inhibition of acetyl-cholinesterase (IC50 μΜ or AChE Inh. %) and lipid peroxidation inhibition (LPI% at 100 μΜ).
| Compound | LOX Inh. | % AChE inh @ 100 μΜ | LPI% @ 100 μΜ |
|---|---|---|---|
|
| 60.5 | 54 | 77 |
|
| 54 | 44 | 51 |
|
| 92 | ||
|
| - | 98 | |
|
| 0.5 | - |
Note: SD < 10%.